Adjuvant endocrine therapy (Q35612311)

9 August 2017

1 reference

title

Adjuvant endocrine therapy (English)

1 reference

9 August 2017

Lars E Rutqvist

1

1 reference

9 August 2017

publication date

1 March 2004

1 reference

Best Practice and Research: Clinical Endocrinology and Metabolism

9 August 2017

published in

1 reference

9 August 2017

volume

18

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

81-95

1 reference

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 r

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Systemic adjuvant treatment for premenopausal node-negative breast cancer. The International Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Preliminary Results From the Cancer Research Campaign Trial Evaluating Tamoxifen Duration in Women Aged Fifty Years or Older With Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Oestrogenic effects of adjuvant tamoxifen in postmenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Aromatase inhibitors and inactivators for breast cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Side Effects of Adjuvant Endocrine Treatment in Premenopausal Breast Cancer Patients: A Prospective Randomized Study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

Guidelines on endocrine therapy of breast cancer EUSOMA.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900046-0

7 January 2021

10.1016/S1521-690X(03)00046-0

Identifiers

DOI

1 reference

9 August 2017

1 reference